nodes	percent_of_prediction	percent_of_DWPC	metapath
Oxymetazoline—HTR1E—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0507	0.0507	CbGpPWpGaD
Oxymetazoline—HTR1E—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0403	0.0403	CbGpPWpGaD
Oxymetazoline—HTR1D—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0344	0.0344	CbGpPWpGaD
Oxymetazoline—HTR1B—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0337	0.0337	CbGpPWpGaD
Oxymetazoline—HTR1E—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0307	0.0307	CbGpPWpGaD
Oxymetazoline—HTR1D—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0273	0.0273	CbGpPWpGaD
Oxymetazoline—HTR1B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0268	0.0268	CbGpPWpGaD
Oxymetazoline—ADRA2B—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0266	0.0266	CbGpPWpGaD
Oxymetazoline—HTR2B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0252	0.0252	CbGpPWpGaD
Oxymetazoline—ADRA2C—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0248	0.0248	CbGpPWpGaD
Oxymetazoline—ADRA1D—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0234	0.0234	CbGpPWpGaD
Oxymetazoline—ADRA2B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0211	0.0211	CbGpPWpGaD
Oxymetazoline—HTR1D—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0208	0.0208	CbGpPWpGaD
Oxymetazoline—HTR1B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0204	0.0204	CbGpPWpGaD
Oxymetazoline—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0203	0.0203	CbGpPWpGaD
Oxymetazoline—ADRA2A—G alpha (i) signalling events—CXCL11—nasal cavity cancer	0.0202	0.0202	CbGpPWpGaD
Oxymetazoline—ADRA2C—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0197	0.0197	CbGpPWpGaD
Oxymetazoline—ADRA1B—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0194	0.0194	CbGpPWpGaD
Oxymetazoline—HTR2B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0192	0.0192	CbGpPWpGaD
Oxymetazoline—ADRA1D—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0178	0.0178	CbGpPWpGaD
Oxymetazoline—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0176	0.0176	CbGpPWpGaD
Oxymetazoline—HTR1E—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0174	0.0174	CbGpPWpGaD
Oxymetazoline—ADRA1A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.0173	0.0173	CbGpPWpGaD
Oxymetazoline—ADRA2B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0161	0.0161	CbGpPWpGaD
Oxymetazoline—ADRA2A—Class A/1 (Rhodopsin-like receptors)—CXCL11—nasal cavity cancer	0.016	0.016	CbGpPWpGaD
Oxymetazoline—HTR1E—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0158	0.0158	CbGpPWpGaD
Oxymetazoline—HTR2C—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0155	0.0155	CbGpPWpGaD
Oxymetazoline—ADRA2C—GPCR ligand binding—CXCL11—nasal cavity cancer	0.015	0.015	CbGpPWpGaD
Oxymetazoline—ADRA1B—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0148	0.0148	CbGpPWpGaD
Oxymetazoline—HTR2A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0134	0.0134	CbGpPWpGaD
Oxymetazoline—ADRA1A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0131	0.0131	CbGpPWpGaD
Oxymetazoline—ADRA2A—GPCR ligand binding—CXCL11—nasal cavity cancer	0.0122	0.0122	CbGpPWpGaD
Oxymetazoline—HTR1D—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0118	0.0118	CbGpPWpGaD
Oxymetazoline—HTR1B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0115	0.0115	CbGpPWpGaD
Oxymetazoline—HTR2B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0108	0.0108	CbGpPWpGaD
Oxymetazoline—HTR1D—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0107	0.0107	CbGpPWpGaD
Oxymetazoline—HTR1B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.0105	0.0105	CbGpPWpGaD
Oxymetazoline—ADRA1D—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0101	0.0101	CbGpPWpGaD
Oxymetazoline—HTR2B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00983	0.00983	CbGpPWpGaD
Oxymetazoline—HTR1E—Signaling Pathways—CXCL11—nasal cavity cancer	0.00931	0.00931	CbGpPWpGaD
Oxymetazoline—ADRA1D—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00915	0.00915	CbGpPWpGaD
Oxymetazoline—ADRA2B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00909	0.00909	CbGpPWpGaD
Oxymetazoline—HTR2C—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00873	0.00873	CbGpPWpGaD
Oxymetazoline—ADRA2C—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00849	0.00849	CbGpPWpGaD
Oxymetazoline—ADRA1B—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00836	0.00836	CbGpPWpGaD
Oxymetazoline—ADRA2B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00826	0.00826	CbGpPWpGaD
Oxymetazoline—HTR2C—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00793	0.00793	CbGpPWpGaD
Oxymetazoline—ADRA2C—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00771	0.00771	CbGpPWpGaD
Oxymetazoline—ADRA1B—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00759	0.00759	CbGpPWpGaD
Oxymetazoline—HTR2A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00758	0.00758	CbGpPWpGaD
Oxymetazoline—ADRA1A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.00743	0.00743	CbGpPWpGaD
Oxymetazoline—ADRA2A—GPCR downstream signaling—CXCL11—nasal cavity cancer	0.0069	0.0069	CbGpPWpGaD
Oxymetazoline—HTR2A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00689	0.00689	CbGpPWpGaD
Oxymetazoline—ADRA1A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00674	0.00674	CbGpPWpGaD
Oxymetazoline—HTR1D—Signaling Pathways—CXCL11—nasal cavity cancer	0.00631	0.00631	CbGpPWpGaD
Oxymetazoline—ADRA2A—Signaling by GPCR—CXCL11—nasal cavity cancer	0.00627	0.00627	CbGpPWpGaD
Oxymetazoline—HTR1B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00618	0.00618	CbGpPWpGaD
Oxymetazoline—HTR2B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00581	0.00581	CbGpPWpGaD
Oxymetazoline—HTR1E—Signaling Pathways—FRS2—nasal cavity cancer	0.00549	0.00549	CbGpPWpGaD
Oxymetazoline—ADRA1D—Signaling Pathways—CXCL11—nasal cavity cancer	0.0054	0.0054	CbGpPWpGaD
Oxymetazoline—ADRA2B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00488	0.00488	CbGpPWpGaD
Oxymetazoline—HTR2C—Signaling Pathways—CXCL11—nasal cavity cancer	0.00469	0.00469	CbGpPWpGaD
Oxymetazoline—ADRA2C—Signaling Pathways—CXCL11—nasal cavity cancer	0.00456	0.00456	CbGpPWpGaD
Oxymetazoline—ADRA1B—Signaling Pathways—CXCL11—nasal cavity cancer	0.00448	0.00448	CbGpPWpGaD
Oxymetazoline—HTR2A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00407	0.00407	CbGpPWpGaD
Oxymetazoline—ADRA1A—Signaling Pathways—CXCL11—nasal cavity cancer	0.00398	0.00398	CbGpPWpGaD
Oxymetazoline—HTR1D—Signaling Pathways—FRS2—nasal cavity cancer	0.00372	0.00372	CbGpPWpGaD
Oxymetazoline—ADRA2A—Signaling Pathways—CXCL11—nasal cavity cancer	0.0037	0.0037	CbGpPWpGaD
Oxymetazoline—HTR1B—Signaling Pathways—FRS2—nasal cavity cancer	0.00364	0.00364	CbGpPWpGaD
Oxymetazoline—HTR2B—Signaling Pathways—FRS2—nasal cavity cancer	0.00342	0.00342	CbGpPWpGaD
Oxymetazoline—ADRA1D—Signaling Pathways—FRS2—nasal cavity cancer	0.00318	0.00318	CbGpPWpGaD
Oxymetazoline—ADRA2B—Signaling Pathways—FRS2—nasal cavity cancer	0.00288	0.00288	CbGpPWpGaD
Oxymetazoline—HTR2C—Signaling Pathways—FRS2—nasal cavity cancer	0.00276	0.00276	CbGpPWpGaD
Oxymetazoline—ADRA2C—Signaling Pathways—FRS2—nasal cavity cancer	0.00269	0.00269	CbGpPWpGaD
Oxymetazoline—ADRA1B—Signaling Pathways—FRS2—nasal cavity cancer	0.00264	0.00264	CbGpPWpGaD
Oxymetazoline—HTR2A—Signaling Pathways—FRS2—nasal cavity cancer	0.0024	0.0024	CbGpPWpGaD
Oxymetazoline—ADRA1A—Signaling Pathways—FRS2—nasal cavity cancer	0.00235	0.00235	CbGpPWpGaD
Oxymetazoline—ADRA2A—Signaling Pathways—FRS2—nasal cavity cancer	0.00218	0.00218	CbGpPWpGaD
